Duke-NUS Medical School

Directory

Tan-Koi Wei Chuen

Assistant Professor, Centre of Regulatory Excellence

weichuen.tankoi@duke-nus.edu.sg

65161679

About

Professional

Research Interests

Teaching

Publications

Bio

Dr. Tan-Koi is Assistant Professor and Lead of Regulatory Systems Strengthening Team at the Centre of Regulatory Excellence in the Duke-NUS Medical School. In her current role, Dr. Tan-Koi leads international initiatives to improve equitable access to biomedical innovations including precision medicine, vaccines and diagnostics through evidence-based policy recommendations and capacity building programmes. Her work has influenced national genetic recommendations to improve public health, with her recent work on vaccine and diagnostic regulation being supported by the Asian Development Bank and the Gates Foundation.

Dr Tan-Koi served as faculty for the ASEAN Vaccine Security and Self-Reliance capacity building programme and the Asia-Pacific Economic Cooperation (APEC) Pharmacovigilance Centre of Excellence Pilot Programme, and published extensively in peer-reviewed journals, book chapters, policy briefs, and market insight reports. With over 20 years of experience across tertiary hospital, national regulatory agency as well as international consulting and technical assistance projects, Dr. Tan-Koi has provided expert advice to ministry of health, national regulatory agencies and industry on policy innovation and regulatory science to advance equitable access to safe, effective and quality-assured biomedical innovations. She is also a member of the Vigilance (VL) Working Group established by the World Health Organization Regulatory Systems Strengthening team.

Prior to her current appointment, Dr. Tan-Koi was Regulatory Consultant and Team Lead for the Regulatory Research (Pharmacogenomics) and Risk Communication teams at Singapore's Health Sciences Authority. Trained in pharmacy at the National University of Singapore, Dr. Tan-Koi practised for over a decade in KK Women's and Children's Hospital. She holds a PhD from the National University of Singapore Saw Swee Hock School of Public Health and is a recipient of the Singapore Ministry of Health (MOH) Health Manpower Development Plan (HMDP) Fellowship (Graduate Research Programme in Public Health).

Education

Doctor of Philosophy

National University of Singapore, Singapore

Directory

Bio

Education

Doctor of Philosophy

Professional Appointment(s)

Regulatory Consultant and Team Lead of the Risk Communication and Regulatory Research Unit;

Content Expert

Lecturer

Membership

Member

Voting Delegate

Research Interests

Teaching

Publications

Regulatory factors affecting sustainable vaccine manufacturing in Asia and the Pacific: Findings from a scoping review and semi-structured interviews.

Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.

Regulation in the age of calamity: Changing the regulatory paradigm.

Regulatory strengthening as a pillar of health system resilience for sustainable immunization.

Promoting collaboration of regulators and patients in improving drug safety and regulatory decision making.

Pandemic Vaccine Development (Refereed Book)

Enhancing Vaccine Regulation for Pandemic Preparedness

Ensuring Sustainable, Locally Relevant Vaccine R&D in Resource-Limited Settings

Pharmacovigilance activities in ASEAN countries.

Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.

Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.

Applications of pharmacogenomics in regulatory science: a product life cycle review.

Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.

Post-vaccination abscess requiring surgical drainage in a tertiary children's hospital in Singapore.

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?

The importance of ethnicity definitions and pharmacogenomics in ethnobridging and pharmacovigilance

A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02.

Pharmacogenetics through a public health lens: from policy to practice.

Directory

Bio

Education

Doctor of Philosophy

Professional Appointment(s)

Regulatory Consultant and Team Lead of the Risk Communication and Regulatory Research Unit;

Content Expert

Lecturer

Membership

Member

Voting Delegate

Research Interests

Teaching

Publications

Regulatory factors affecting sustainable vaccine manufacturing in Asia and the Pacific: Findings from a scoping review and semi-structured interviews.

Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.

Regulation in the age of calamity: Changing the regulatory paradigm.

Regulatory strengthening as a pillar of health system resilience for sustainable immunization.

Promoting collaboration of regulators and patients in improving drug safety and regulatory decision making.

Pandemic Vaccine Development (Refereed Book)

Enhancing Vaccine Regulation for Pandemic Preparedness

Ensuring Sustainable, Locally Relevant Vaccine R&D in Resource-Limited Settings

Pharmacovigilance activities in ASEAN countries.

Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.

Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.

Applications of pharmacogenomics in regulatory science: a product life cycle review.

Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.

Post-vaccination abscess requiring surgical drainage in a tertiary children's hospital in Singapore.

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?

The importance of ethnicity definitions and pharmacogenomics in ethnobridging and pharmacovigilance

A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02.

Pharmacogenetics through a public health lens: from policy to practice.

Browser not supported

Modern websites need modern browsers